Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arcutis Biotherapeutics, Inc. - Common stock
(NQ:
ARQT
)
29.31
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
50 Stocks Moving In Wednesday's Mid-Day Session
↗
May 25, 2022
Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) gained 178.3% to $0.3762 as the company announced it increased retail distribution across Canada with Loblaw Companies.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
March 18, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast
↗
December 23, 2021
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has obtained a $225 million term loan facility from SLR Capital Partners (SLR). This additional capital...
Via
Benzinga
Arcutis' Roflumilast Cream For Psoriasis Goes Under FDA Review
↗
December 23, 2021
The FDA has accepted Arcutis Biotherapeutics Inc's (NASDAQ: ARQT) marketing application seeking approval for roflumilast cream for psoriasis in adults and...
Via
Benzinga
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
↗
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
5 Stocks To Watch For December 23, 2021
↗
December 23, 2021
Some of the stocks that may grab investor focus today are: Banner Corporation (NASDAQ: BANR) reported a buyback of 1.71 million shares, which is the equivalent of around 5% of...
Via
Benzinga
Is Now the Time to Bet on Arcutis Biotherapeutics?
↗
September 18, 2021
Management has high hopes for the company's treatment candidates for dermatological conditions, but can they get one to market before its cash cushion is depleted?
Via
The Motley Fool
Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study
↗
July 01, 2021
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) will terminate the Phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo. The study was ...
Via
Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
↗
September 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2021
↗
June 30, 2021
Upgrades For Taiwan Semiconductor Manufacturing Co Ltd (NYSE:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021
↗
May 27, 2021
Upgrades Craig-Hallum upgraded the previous rating for NVIDIA Corp (NASDAQ:NVDA) from Hold to Buy. In the first quarter, NVIDIA showed an EPS of $3.66, compared to $1.80...
Via
Benzinga
55 Biggest Movers From Friday
↗
May 03, 2021
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) jumped 45.5% to close at $49.80 on Friday after dropping around 22% on Thursday. Brooklyn ImmunoTherapeutics acquired...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
April 30, 2021
Gainers Motus GI Hldgs (NASDAQ:MOTS) stock moved upwards by 30.17% to $1.42 during Friday's regular session. As of 12:31 EST, this security is trading at a volume of...
Via
Benzinga
38 Stocks Moving In Friday's Mid-Day Session
↗
April 30, 2021
Gainers Image Sensing Systems, Inc. (NASDAQ: ISNS) rose 29.2% to $5.93 after the company announced it initiated a quarterly dividend of $0.12 per share, authorized a 220,000...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
April 30, 2021
Gainers Motus GI Hldgs (NASDAQ:MOTS) stock increased by 46.78% to $1.6 during Friday's pre-market session. The market value of their outstanding shares is at $74.7...
Via
Benzinga
Arcutis' Roflumilast Foam Improves Scalp, Body Psoriasis As Early As Two Weeks After Treatment Initiation
↗
April 23, 2021
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has announced the presentation of new safety and efficacy data of roflumilast foam to treat scalp and body...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today